OMedLive

CME Presentations

Head and Neck Cancer


Presentations

  • CME
    1.0

    Effective Management Strategies for Head and Neck Cancer

    Speakers:Jared Weiss, MD, Section Chief of Thoracic and Head/Neck Oncology
    Robert I. Haddad, MD, Associate Professor of Medicine

    Duration: 60 minutes

    Presented on: August 24, 2017

  • CME
    1.0

    The New Paradigm of Immunotherapy for Head and Neck Cancer

    Speakers:Jared Weiss, MD, Section Chief of Thoracic and Head/Neck Oncology
    Robert I. Haddad, MD, Associate Professor of Medicine

    Duration: 60 minutes

    Presented on: August 24, 2017


Speakers

  • Jared Weiss, MD

    Jared Weiss, MD

    Jared Weiss, MD

    Section Chief of Thoracic and Head/Neck Oncology

    Jared Weiss, MD, is an associate professor and section chief of thoracic and head/neck oncology at the University of North Carolina School of Medicine at Chapel Hill. Clinically, Dr Weiss focuses on treating patients with head and neck cancers and lung cancers. His research concentrates on bringing new and promising treatments to patients, while focusing on outcomes such as survival and quality of life. He is vice president of cancergrace.org, a global resource with the goal of increasing patient education and family information on cancer, and serves on the executive board of the Lung Cancer Initiative. Dr Weiss received his doctor of medicine at Yale University School of Medicine in New Haven, Connecticut, and his BS in neuroscience at Brown University in Providence, Rhode Island.
  • Robert I. Haddad, MD

    Robert I. Haddad, MD

    Robert I. Haddad, MD

    Associate Professor of Medicine

    Robert I. Haddad, MD, is an associate professor of medicine at Harvard Medical School, and is Disease Center Leader of the Head and Neck Oncology Program and a member of the Department of Adult Oncology at the Dana-Farber Cancer Institute in Boston, Massachusetts. Dr Haddad’s research activities involve the use of induction chemotherapy for patients with locally advanced head and neck cancer and the development of novel immunotherapeutic agents for treating locally advanced disease. He is a member or several professional societies, and has been instrumental in the development, execution and publication of numerous phase II and III trials in head and neck cancer. Dr Haddad received his medical degree from St. Joseph University French School of Medicine in Beirut.

CME Information

 

Head and Neck Cancer: Current Evidence, Recent Developments, and Future Directions

Jointly provided by Postgraduate Institute for Medicine and PlatformQ Health Education, LLC

 

ACKNOWLEDGEMENT This activity is supported by an independent educational grants from Bristol–Myers Squibb and Merck & Co.

TUITION Complimentary

ACCREDITATION STATEMENT This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and PlatformQ Health Education, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS Live Internet Activity The Postgraduate Institute for Medicine designates this live activity for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Enduring Material The Postgraduate Institute for Medicine designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

DATE OF RELEASE/EXPIRATION Live Activity Session I: Effective Management Strategies for Head and Neck Cancer Thursday, August 24, 2017 from 1:00pm – 2:00pm EDT. Session II: The New Paradigm of Immunotherapy for Head and Neck Cancer Thursday, August 24, 2017 from 2:00pm – 3:00pm EDT. Enduring Material Session I: The enduring material will be available from August 24, 2017 – February 24, 2018. Session II: The enduring material will be available from August 24, 2017 – February 24, 2018.

LEARNING OBJECTIVES At the conclusion of this activity, participants will be able to:

Assess the safety and efficacy of available and emerging multimodal regimens, including immunotherapy, for patients with head and neck cancer
Utilize strategies to optimally sequence available regimens for the therapeutic management of head and neck cancer
Evaluate the latest clinical efficacy and safety data on the use of immune checkpoint inhibitors in head and neck cancer
Examine anticipated adverse events related with immune checkpoint inhibitors in head and neck cancer

TARGET AUDIENCE This activity is intended for medical and radiation oncologists, head and neck surgeons, otolaryngologists, ear, nose and throat (ENT) specialists, and other health care professionals (primary care providers, physicians–in–training, oncology nurses, nurse practitioners, pharmacists, physician assistants, etc.) involved and/or interested in the therapeutic management of patients with head and neck cancer.

ESTIMATED TIME TO COMPLETE This activity consists of two sessions, each which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION There are no fees to participate in this activity. To participate in the activity, go to http://www.OMedLive.com/. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. It is estimated that this module will take approximately 1 hours to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the post-test.

HARDWARE/SOFTWARE REQUIREMENTS Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

DISCLOSURE OF CONFLICTS OF INTEREST Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or Presenter Reported Financial Relationship
Jared Weiss, MD Associate Professor of Medicine Section Chief of Thoracic and Head/Neck Oncology UNC Lineberger Comprehensive Cancer Center Vice President CancerGrace.org Advocate and Board Member Lung Cancer Initiative of North Carolina Consultant: AstraZeneca, Celgene, EMD Serono, Inivata Contracted Research: Astellas, AstraZeneca, Celgene, Merck & Co., Novartis, Pfizer, Inc.
Robert I. Haddad, MD Disease Center Leader, Head and Neck Oncology Program Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School

Consultant: AstraZeneca, Bristol-Myers Squibb, Eisai, Merck & Co., Pfizer, Inc. Contracted Research: AstraZeneca, Bristol-Myers Squibb, Celgene, Merck & Co., Pfizer, Inc.

 

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Planner Reprted Financial Relationship
Hamsa Jaganathan, PhD Medical Director PlatformQ Health Education, LLC None

The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

The following PlatformQ Health Education, LLC planner, Elizabeth del Nido, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

DISCLOSURE OF UNAPPROVED/OFF LABEL USE (if applicable): This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

CONTACT INFORMATION Accreditation Support: Please contact the Postgraduate Institute for Medicine at www.pimed.com.

Technical Support: For any technical issues or issues with your CME Certificate, please contact OMedLive at 877-394-1306 or at Support@OMedLive.com.